Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

• 1 Concord Hospital, Sydney, NSW.
• 2 University of Tasmania, Launceston, TAS.
• 3 Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania.
• 4 Beth Israel Deaconess Medical Center, Boston, Mass, USA.

---

• 1. Gyorki DE, Henderson MA. Sentinel lymph node biopsy for melanoma: an important risk-stratification tool. Med J Aust 2014; 201: 442-444. <MJA full text>
• 2. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Multicenter Selective Lymphadenectomy Trial (MSLT). http://clinicaltrials.gov/ct2/show/NCT00275496?term=NCT00275496&rank=1 (accessed Nov 2014).
• 3. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609.
• 4. Sladden M, Zagarella S, Popescu C, Bigby M. No survival benefit for melanoma patients undergoing sentinel lymph node biopsy: critical appraisal of the multicenter selective lymphadenectomy trial-1 final report. Br J Dermatol 2015. In press.
• 5. Mitra A, Conway C, Walker C, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 2010; 103: 1229-1236.